XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Note 7 - Stockholder's Equity (Tables)
9 Months Ended
Sep. 30, 2025
Notes Tables  
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]
  

Number of

  

Weighted

 
  

Units and

  

Average Grant

 
  

Awards

  

Date Fair Value

 

Unvested balance at December 31, 2024

  236,028  $3.44 

Vested

  (284)  85.50 

Unvested balance at March 31, 2025

  235,744  $3.34 

Forfeited

  (212)  171.94 

Unvested balance at June 30, 2025

  235,532  $3.19 

Unvested balance at September 30, 2025

  235,532  $3.19 
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
          

Weighted

     
          

Average

     
     

Weighted

  

Remaining

  

Aggregate

 
  

Number

  

Average

  

Contractual

  

Intrinsic Value

 
  

of Options

  

Exercise Price

  

Term (years)

  

(in thousands)

 

Outstanding at December 31, 2024

  256,474  $9.74   9.6  $ 

Outstanding at September 30, 2025

  256,474  $9.74   8.9  $ 

Expected to vest

  162,624  $5.84   8.9  $ 

Exercisable

  93,850  $16.48   8.8  $ 
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
  

For the Three Months Ended

  

For the Nine Months Ended

 
  

September 30,

  

September 30,

 
  

2025

  

2024

  

2025

  

2024

 

Research and development

 $31  $89  $102  $179 

General and administrative

  132   242   421   535 

Total stock-based compensation expense

 $163  $331  $523  $714 
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
      

Weighted

     
      

Average

  

Aggregate

 
      

Exercise

  

Intrinsic Value

 
  

Warrants

  

Price

  

(in thousands)

 

Outstanding, December 31, 2024

  1,476,200  $8.64  $ 

Outstanding, September 30, 2025

  1,476,200  $8.64  $